Rekom Biotech

Executive Summary

Rekom Biotech, founded in 2015 and headquartered in Barcelona, Spain, is a private biotechnology company focused on the design and manufacturing of high-quality raw materials for the in vitro diagnostics (IVD) industry. The company's product portfolio includes recombinant proteins, antibodies, and allergens, all validated for use as IVD reagents. Additionally, Rekom Biotech offers custom development and manufacturing services, enabling clients to obtain tailored reagents for their diagnostic platforms. By specializing in these critical components, the company plays a key role in the supply chain for diagnostic test manufacturers, supporting the development of accurate and reliable assays for a range of diseases and conditions. Given its niche focus and established operations in the growing IVD market, Rekom Biotech is well-positioned for steady growth. While financial details are not publicly available, the company’s specialization in validated reagents positions it as a potential partner for diagnostic firms seeking high-quality inputs. Key near-term catalysts could include the launch of new recombinant antigens for emerging pathogens, expansion of custom service capabilities, or achievement of ISO 13485 certification to broaden market access. These developments would likely enhance the company's competitive standing and revenue potential.

Upcoming Catalysts (preview)

• TBDLaunch of new recombinant antigens for infectious disease diagnostics70% success
• TBDExpansion of custom development service contracts with diagnostic companies65% success
• TBDAchievement of ISO 13485 certification for quality management systems80% success